Navigation Links
Xencor Reports Second Quarter 2014 Financial Results
Date:7/31/2014

XmAb® technology. Xencor's internally-discovered programs include XmAb5871, in Phase 1b/2a clinical trials for the treatment of Rheumatoid arthritis and lupus, XmAb7195 in Phase 1a development for the treatment of asthma, and XmAb5574/MOR208 which has been licensed to Morphosys AG and is in Phase 2 clinical trials for the treatment of acute lymphoblastic leukemia and non-Hodgkin lymphoma. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. Xencor partners include Amgen, Merck, Janssen R&D LLC, Alexion and Boehringer Ingelheim. For more information, please visit www.xencor.com.

Forward Looking StatementsStatements contained in this press release regarding matters that are not historical facts are forward-looking statements within the meaning of applicable securities laws, including the quotation from our President and CEO and any expectations relating to our business, research and development programs, partnering efforts or our capital requirements. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements and the timing of  events to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. Such risks include, without limitation, the risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and other risks described in Xencor's public securities filings. All forward-looking statements are based on Xencor's current information and belief as well as assumptions made by Xencor. Readers are cautioned not to place undue reliance on such statements and Xencor disclaims any intention or obligation to update or revise any forward-looking
'/>"/>

SOURCE Xencor Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Xencor to Host Second Quarter 2014 Financial Results Webcast and Conference Call
2. Xencor Appoints Kurt Gustafson to Board of Directors; Promotes John Desjarlais to Chief Scientific Officer
3. Xencor, Inc. Announces Closing of Initial Public Offering
4. Pharmacyclics Reports Second Quarter 2014 Results
5. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014
6. Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015
7. HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013
8. Endo Reports Second Quarter Financial Results
9. Columbia Laboratories Reports Second Quarter 2014 Financial Results
10. Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results
11. Hospira Reports Second-Quarter 2014 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014 Adaptive Biotechnologies, ... Sequencing (NGS) to profile the adaptive immune system, is ... as Chief Commercial Officer (CCO). The addition of ... recent key hires from leading global healthcare companies, including ... (General Counsel) from Genomic Health and Sean ...
(Date:9/16/2014)... Sept. 16, 2014 EHE International, the recognized leader ... physician network, today announced that David Abrams M.D . ... an EHE-certified preventive care center. Through David Abrams M.D ... region now have greater access to EHE,s preventive care programs ... is proud to add Dr. Abrams M.D. to its growing ...
(Date:9/16/2014)... , Sept. 16, 2014 QPID Health , ... to new headquarters in Boston and ... headquarters will be at 175 Franklin Street in ... marketing teams. QPID Health,s new Southern California ... Carlsbad.  The expansion will help meet the demands of customers ...
Breaking Medicine Technology:Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 2Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 3EHE International Certifies David Abrams M.D. as Its Newest Partner 2QPID Health Announces Major Office Expansion in Boston and Opens Facility in San Diego 2
... 3, 2010 Cardiogenesis Corporation (OTCQB: CGCP), a leading ... diffuse coronary artery disease, today reported financial results for ... 30, 2010. Revenue for the third quarter ... year third quarter revenue of $2,134,000.  Gross margin was ...
... NxStage Medical, Inc. (Nasdaq: NXTM ), ... that it has expanded its Medisystems® in-center product portfolio ... to the terms of the strategic Agreement with Vasc-Alert ... in the United States.   Vasc-Alert, a ...
Cached Medicine Technology:Cardiogenesis Reports Third Quarter 2010 Results 2Cardiogenesis Reports Third Quarter 2010 Results 3Cardiogenesis Reports Third Quarter 2010 Results 4Cardiogenesis Reports Third Quarter 2010 Results 5Cardiogenesis Reports Third Quarter 2010 Results 6NxStage® Expands Product Portfolio With Innovative Patient Access Surveillance Solution From Vasc-Alert™ 2NxStage® Expands Product Portfolio With Innovative Patient Access Surveillance Solution From Vasc-Alert™ 3
(Date:9/17/2014)... September 17, 2014 ICS Learning Group, ... for Excellence in Training for the Best Use of ... based on an online operational safety training module that ... forklift operation. Using an approach that combined realistic ... module that was similar to a video game, including ...
(Date:9/17/2014)... September 17, 2014 MicroSourcing International, Inc., ... Process Outsourcing (BPO) services in the Philippines, announced today ... Senior Vice President – North America to further develop ... is a 15 year veteran of the offshore outsourcing ... helping companies, ranging in size from small businesses to ...
(Date:9/17/2014)... CA (PRWEB) September 17, 2014 ... high throughput research solutions for drug development, today ... Module 3 (CM3) Reaction Screening System to both ... to the Texas community. Freeslate’s high throughput system ... area of reaction screening and optimization for small ...
(Date:9/17/2014)... Hallandale Beach, FL (PRWEB) September 17, 2014 ... products, is pleased to announce their newest addition to ... This conditioner is formulated with nourishing and beneficial ... jojoba oils to provide hair with ample moisture, while ... Volumizing Biotin Conditioner is formulated to complement the ...
(Date:9/17/2014)... 2014 1st-Dress.com, one of the most ... long bridesmaid dresses recently. All the fresh ... quality materials. Furthermore, they are offered at deeply discounted ... , The firm is striving to provide a ... its workers never compromises on style, quality and customer ...
Breaking Medicine News(10 mins):Health News:ICS Learning Group Wins Gold in the 2014 Brandon Hall Excellence Competition for Best Use of Games and Simulations for Learning 2Health News:MicroSourcing Appoints New Senior Vice President of North America 2Health News:Baylor University Selects Freeslate Reaction Screening System to Support New High Throughput Screening Lab 2Health News:Luxury Barber Adds New Regenepure Biotin Conditioner to Their Selection of Grooming Products 2Health News:2014 Long Bridesmaid Dresses Available Online At 1st-Dress.com 2
... interests and those of the pharmaceutical industry has got sharper ... a bill that would clothe the Food and Drug Administration ... two years before advertising a newly approved drug directly to ... powers to fine companies that fail to do post-approval studies ...
... the most malignant diseases which are responsible for number of ... on this subject. A new study suggests that true biological ... have been confounded by Dr. Tim Byers, of the University ... ,It is not due to the disparity in the access ...
... vigorous arguments never seem to leave the Hormone Replacement Therapy (HRT) ... ‘notoriety’. ,Yet say some experts, don’t be in a ... them, hormone replacement therapy may have led to the deaths of ... 1991. ,In an article said to be the first ...
... pain and agony begin to subside over Monday’s ghastly student massacre ... killer Cho Seung-Hui began to take form. , The ... any stronger than this point of time. At the same time, ... ,The fact that Cho was a ‘disturbed’ student was not ...
... from vegetable sources, is touted as a more eco-friendly fuel, ... use of ethanol could actually pose a threat to human ... that eco-friendly after all. The journey for ever is hitting ... the US shows that it could be damaging to human ...
... small percentage of food imported into the United States is ... of some form or the other. What happens to the ... ,Recently, the United States has been reeling under the effect ... This could also be due to lenient food laws in ...
Cached Medicine News:Health News:Moratorium Proposed on Advertisements of Newly Approved Drugs 2Health News:Expert Warn- Odds Still Stacked Against Hormone Replacement Therapy 2Health News:Expert Warn- Odds Still Stacked Against Hormone Replacement Therapy 3Health News:Virginia Tech. Shooter -Human Rights or Innocent Lives 2Health News:Ethanol Could Be Damaging for Human Health, New Study Says 2Health News:Ethanol Could Be Damaging for Human Health, New Study Says 3
XL STABI Hydrophilic Acrylic Lens....
TRIPODE Hydrophilic Acrylic Lens....
Biocryl™ Acrylic Foldable Lens....
The STAAR ELASTIMIDE lens, combines the best of foldable lens technology with traditional design. This lens contains a cast-molded, silicone optic with modified Polyimide haptics....
Medicine Products: